Sareum Holdings plc
("Sareum" or the "Company")
Exercise of Warrants
Cambridge, UK, 9 July 2025 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, announces that it has received a notice to exercise certain warrants to subscribe for a total of 1,000,000 new ordinary shares in the capital of the Company at a price of 12.5 pence per New Ordinary Share (the "New Ordinary Shares") for a total consideration to the Company of £125,000.
Admission and Total Voting Rights
Application has been made to the London Stock Exchange plc for the admission of the 1,000,000 New Ordinary Shares to trading on AIM ("Admission"). It is expected that Admission will occur at 8.00 a.m. (London time) on or around Monday 14 July 2025. The New Ordinary Shares will rank pari passu with the existing ordinary shares.
Immediately following Admission, the total number of ordinary shares in issue will be 135,411,893. and the total number of voting rights will therefore be135,411,893 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
For Further Information:
|
Sareum Holdings plc Stephen Parker, Executive Chairman |
01223 497700 ir@sareum.co.uk |
|
Strand Hanson Limited (Nominated Adviser) James Dance / James Bellman
|
020 7409 3494 |
|
Oberon Capital (Broker) Mike Seabrook / Nick Lovering
|
020 3179 5300 |
|
ICR Healthcare (Financial PR) Jessica Hodgson / Davide Salvi |
020 3709 5700 |
About Sareum
Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer.
The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases and has entered Phase 1a/b clinical development with an initial focus on psoriasis.
Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy.
The Company also holds the license for SRA737, a clinical-stage Checkpoint kinase 1 inhibitor that targets cancer cell replication and DNA damage repair mechanisms.
Sareum Holdings plc is based in Cambridge, UK, and is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
